"I don't recall them ever discussing or presenting before on apabetalone or BET protein regulation of hepatic CRP expression. Very interesting." 

Not entirely correct. A quick google search reminded me of this abstract and paper that documented apabetalone's effect to reduce CRP mRNA and circulating protein in primary human hepatocytes treated with apabetalone and plasma of human patients treated with apabetalone, respectively. It is likely that the abstract next week at Vascular Discovery will go into more focused molecular detail of the direct involvement of BET proteins in the regulation of CRP gene expression in liver cells. Very cool

Abstract 15031: Apabetalone (RVX-208) Reduces Expression of Acute Phase Response Markers in vitro and in Patients With Cardiovascular Disease

https://www.ahajournals.org/doi/abs/10.1161/circ.134.suppl_1.15031

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585290/